Outlook Therapeutics, Inc.
OTLK
$0.39
$0.0411.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 205.70K | 1.41M | 1.51M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 205.70K | 1.41M | 1.51M | -- | -- |
| Cost of Revenue | 18.13M | 24.13M | 29.76M | 33.39M | 33.39M |
| Gross Profit | -17.93M | -22.72M | -28.25M | -33.39M | -33.39M |
| SG&A Expenses | 36.60M | 39.94M | 39.97M | 38.65M | 36.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.14M | 68.48M | 74.13M | 76.44M | 82.99M |
| Operating Income | -58.94M | -67.06M | -72.62M | -76.44M | -82.99M |
| Income Before Tax | -104.41M | -63.98M | -43.44M | 21.12M | -46.81M |
| Income Tax Expenses | -1.55M | -1.55M | 2.80K | 2.80K | 2.80K |
| Earnings from Continuing Operations | -102.86 | -62.42 | -43.44 | 21.12 | -46.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.86M | -62.42M | -43.44M | 21.12M | -46.81M |
| EBIT | -58.94M | -67.06M | -72.62M | -76.44M | -82.99M |
| EBITDA | -58.82M | -66.94M | -72.51M | -76.32M | -82.87M |
| EPS Basic | -2.71 | -1.61 | -1.09 | 1.37 | -5.14 |
| Normalized Basic EPS | -1.60 | -0.95 | -0.59 | 0.70 | -0.82 |
| EPS Diluted | -2.72 | -1.62 | -1.09 | -1.43 | -7.94 |
| Normalized Diluted EPS | -1.60 | -0.95 | -0.59 | 0.61 | -0.91 |
| Average Basic Shares Outstanding | 175.23M | 139.26M | 115.79M | 102.06M | 85.46M |
| Average Diluted Shares Outstanding | 175.23M | 139.26M | 115.79M | 104.31M | 87.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |